Physician profile
Christina Mb Wang
NPI 1356853527
$256,911.54
in general payments reported to CMS, 2019-2025
24 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $36K · 2023: $55K · 2024: $73K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $65K · Consulting Fee: $27K · Food and Beverage: $15K · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,499.05 |
| Travel and Lodging | $64,577.98 |
| Consulting Fee | $27,080.00 |
| Food and Beverage | $15,421.52 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $202,713.07 | 2021-2025 | Epclusa, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $44,982.77 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Indivior INC. | $3,797.09 | 2021-2025 | Sublocade, Perseris |
| Abbvie INC. | $1,606.05 | 2021-2025 | |
| Alkermes, INC. | $1,096.70 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $568.51 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $430.88 | 2023-2025 | Uzedy, Austedo Xr |
| Janssen Products, Lp | $284.95 | 2021-2022 | |
| Abbott Laboratories | $228.00 | 2024 | Proclaim |
| Neurocrine Biosciences, INC. | $209.19 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.71 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $172.67 | 2024-2025 | Cobenfy |
| Janssen Biotech, INC. | $171.88 | 2021-2023 | Symtuza, Prezcobix |
| Intercept Pharmaceuticals, INC. | $117.75 | 2023 | Ocaliva |
| Otsuka America Pharmaceutical, INC. | $115.99 | 2022-2025 | Rexulti, Abilify Maintena |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $49.97 | 2025 | Fanapt |
| Janssen Scientific Affairs, LLC | $32.16 | 2021-2022 | |
| Insmed, INC. | $26.52 | 2022 | |
| Pharmacosmos Therapeutics INC. | $25.83 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $24.98 | 2025 | Pifeltro |
| Braeburn INC. | $21.03 | 2025 | Brixadi |
| Dynavax Technologies Corporation | $20.20 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.82 | 2023 | Nuzyra |
| Lundbeck LLC | $17.82 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.